Which chemotherapeutic agent is most commonly associated with paralytic ileus: (a) cyclophosphamide, (b) vinca alkaloids, (c) methotrexate, (d) cisplatin, or (e) doxorubicin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paralytic Ileus as a Complication of Chemotherapeutic Agents

Vinca alkaloids (b) are the chemotherapeutic agents most commonly associated with paralytic ileus.

Mechanism and Evidence for Vinca Alkaloids

  • Vinca alkaloids (vincristine, vinblastine, vinorelbine) bind to tubulin, prevent microtubule formation, and inhibit mitosis, leading to apoptosis, but also affect the autonomic nervous system causing neurotoxicity 1
  • Vincristine specifically causes neuropathy in approximately 27.8% of patients, with constipation (3.5%) and paralytic ileus being recognized adverse effects 1, 2
  • Multiple case reports document paralytic ileus as a direct complication of vinca alkaloid administration, particularly vincristine 3, 4, 5
  • Vincristine-induced paralytic ileus can occur even at low doses (0.16 mg/m²) in susceptible patients 3

Risk Factors and Mechanisms

  • Concomitant use of azole antifungal agents significantly increases the risk of vinca alkaloid-induced neurotoxicity including paralytic ileus by inhibiting CYP3A4, which delays metabolism and excretion of vinca alkaloids 2
  • Pre-existing autonomic neuropathy (such as in Parkinson's disease) may predispose patients to vinca alkaloid-induced paralytic ileus 3
  • The paralytic ileus results from autonomic neuropathy affecting the myenteric plexus of the intestine 3, 5

Management Considerations

  • Prophylactic laxatives, particularly magnesium oxide at doses >2000 mg/day, may help prevent constipation in patients receiving chemotherapy regimens containing vinca alkaloids 6
  • Treatment options for established vincristine-induced paralytic ileus include fiberoptic colonoscopy with enema administration and intravenous prostaglandin F2 alpha 4
  • Temporary discontinuation of azole antifungal agents during vinca alkaloid treatment may reduce the frequency of severe constipation (p=0.0308) and paralytic ileus (p=0.0967) 2

Other Chemotherapeutic Agents and Gastrointestinal Effects

  • Anthracyclines (like doxorubicin) are associated with cardiac arrhythmias but have a lower incidence of gastrointestinal toxicity (15% all-grade diarrhea) 1
  • Cyclophosphamide is primarily associated with hemorrhagic cystitis and gonadal toxicity rather than paralytic ileus 1, 7
  • Methotrexate is primarily associated with mucositis and hepatotoxicity rather than paralytic ileus 1
  • Cisplatin is associated with nausea/vomiting and peripheral neuropathy but has a lower incidence of paralytic ileus compared to vinca alkaloids 1

Clinical Implications

  • Patients receiving vinca alkaloids should be monitored for early signs of autonomic neuropathy including constipation 2, 6
  • Prophylactic measures should be considered in patients receiving CHOP or CHOP-like regimens (which contain vincristine) to prevent progression to paralytic ileus 6
  • Special caution is warranted when administering vinca alkaloids to patients with pre-existing autonomic neuropathy or those concurrently receiving medications that inhibit CYP3A4 2, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Vincristine-induced paralytic ileus in Parkinson's disease.

Parkinsonism & related disorders, 1997

Research

[Paralytic ileus due to vinorelbine].

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005

Guideline

Fertility After Chemotherapy with Epirubicin and Ifosfamide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.